1don MSN
Some VA therapists and patients say their treatment sessions are being limited, raising alarm
An edge comes to Michael’s voice when he speaks about his time serving in Afghanistan and his struggles living with ...
Disasters or emergency situations not only cause physical harm but also significantly affect mental health. One in every five ...
Wilmington Star-News on MSN
How Southport can cope with its grief and trauma following a mass shooting
A mass shooting occurred in the small, seaside city of Southport on Sept. 27, and its impact may be felt for weeks or months ...
A copy of the Company’s presentation will be available under the Presentations tab of the Tonix website at https://ir.tonixpharma.com/presentations.
FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin ...
FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien ...
A copy of the Company’s presentation will be available under the Presentations tab of the Tonix website at https://ir.tonixpharma.com/presentations following the conference. Additional meeting ...
CHATHAM, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a ...
The Chosun Ilbo on MSN
Parent's Malicious Complaints Over Smoking Discipline Prompt Teacher Protection Calls
A parent of a high school student has been reported for filing complaints accusing a teacher of human rights violations and child abuse after the teacher disciplined the student for smoking. On the ...
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ...
Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results